Company intelligence / Profile preview
Alnylam Pharmaceuticals
Cambridge, Massachusetts, United Statesalnylam.ca ↗
- Ownership
- Public · ALNY
- Employees
- ~2100
- Development stage
- Commercial
01
Overview
Alnylam is the global leader in RNA interference therapeutics with five approved medicines as of 2025. Its drugs have demonstrated significant efficacy for rare genetic diseases such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and cardiovascular disease. The company continues to expand its clinical pipeline into new indications and organ systems beyond the liver
- Therapeutic areas
- Rare DiseasesCardiovascular
- Modalities
- RNA interference (RNAi)Small interfering RNA (siRNA)
- Industry
- Biotech
02
Drug pipeline
49 assets48 more assets in the full pipeline.
Request access →03
Partnerships
Novartis (Leqvio)Regulus Therapeutics (co-founded with Ionis)past partnerships with Medtronic, Biogen Idec/Biogen Inc., Hoffmann-La Roche/Ionis Pharmaceuticals
04
Financials
- Market cap
- $33.1B
- Total revenue
- $1.3B
- Enterprise value
- $31.1B
Beyond the preview
Go deeper on Alnylam Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alnylam Pharmaceuticals.